UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 14, 2022
Renovacor, Inc.
(Exact name of Registrant as Specified in Its
Charter)
|
|
|
|
|
Delaware |
|
001-39271 |
|
83-3169838 |
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
201 Broadway, Suite 310
Cambridge, Massachusetts
|
|
02139 |
(Address of
Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area
Code: (610) 424-2650
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☒ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001
per share |
|
RCOR |
|
NYSE American LLC |
Warrants to purchase one share
of common stock at an exercise price of $11.50 |
|
RCOR.WS |
|
NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 |
Regulation FD Disclosure.
|
On October 14, 2022, Renovacor, Inc. (the “Company,” or
“Renovacor”) updated information reflected in a slide presentation,
which is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated
herein by reference. Representatives of the Company will use the
updated presentation in various meetings from time to time.
The information furnished pursuant to Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, and shall not be deemed
to be incorporated by reference in any filing under the Securities
Act of 1933, as amended, or Exchange Act, except as expressly set
forth by specific reference in such filing.
Important Additional Information Regarding the Transaction Will
Be Filed With the SEC
In connection with the proposed transaction between Renovacor and
Rocket Pharmaceuticals, Inc. (“Rocket”), Renovacor and Rocket have
filed relevant materials with the SEC, including a Rocket
registration statement on Form S-4 that includes a joint proxy
statement of Renovacor and Rocket and also constitutes a prospectus
of Rocket, and a definitive proxy statement will be mailed to
stockholders of Renovacor and Rocket, respectively. INVESTORS AND
SECURITY HOLDERS OF RENOVACOR AND ROCKET ARE URGED TO READ THE
JOINT PROXY STATEMENT/PROSPECTUS THAT HAS BEEN INCLUDED IN THE
REGISTRATION STATEMENT ON FORM S-4 AND OTHER RELEVANT DOCUMENTS FILED
OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED
TRANSACTION OR INCORPORATED BY REFERENCE IN THE JOINT PROXY
STATEMENT/PROSPECTUS (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN
THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, THE PARTIES
TO THE PROPOSED TRANSACTION AND THE RISKS ASSOCIATED WITH THE
PROPOSED TRANSACTION. Investors and security holders will be able
to obtain, without charge, a copy of the registration statement,
the joint proxy statement/prospectus and other relevant documents
filed with the SEC (when available) from the SEC’s website at
http://www.sec.gov. Copies of the documents filed with the
SEC by Renovacor will be available free of charge on Renovacor’s
internet website at www.renovacor.com under the tab
“Investor & Media - Financials” or by contacting
Renovacor’s Investor Relations Department at
investors@renovacor.com. Copies of the documents filed with
the SEC by Rocket will be available free of charge on Rocket’s
internet website at www.rocketpharma.com under the tab
“Investors - SEC Filings”.
Participants in the Solicitation
Renovacor, Rocket and certain of their directors, executive
officers and other members of management may be deemed to be
participants in the solicitation of proxies with respect to the
proposed transaction. Information regarding the persons who may,
under the rules of the SEC, be deemed participants in the
solicitation of the shareholders of Renovacor or Rocket in
connection with the proposed transaction, including a description
of their direct or indirect interests, by security holdings or
otherwise, have been set forth in the joint proxy
statement/prospectus that has been filed with the SEC. Information
regarding Renovacor’s directors and executive officers is contained
in Renovacor’s definitive proxy statement, which was filed with the
SEC on April 14, 2022, and Renovacor’s Current Reports on Form
8-K, filed with the SEC on
March 28, 2022 and June 3, 2022 (as amended on
June 24, 2022). Information regarding Rocket’s directors and
executive officers is contained in Rocket’s definitive proxy
statement, which was filed with the SEC on April 29, 2022.
Security holders and investors may obtain additional information
regarding the interests of such persons, which may be different
than those of Renovacor’s or Rocket’s security holders generally,
by reading the joint proxy statement/prospectus and other relevant
documents regarding the transaction, which will be filed with the
SEC. You may obtain these documents (when they become available)
free of charge through the website maintained by the SEC at
http://www.sec.gov and from the Investor Relations websites
of Rocket or Renovacor as described above.
No Offer or Solicitation
This communication is not intended to and does not constitute an
offer to sell or the solicitation of an offer to subscribe for or
buy or an invitation to purchase or subscribe for any securities or
the solicitation of any vote or approval in any jurisdiction
pursuant to the proposed transaction or otherwise, nor shall there
be any sale, issuance
or transfer of securities in any jurisdiction in contravention of
applicable law. This communication does not constitute a prospectus
or prospectus equivalent document. No offering of securities shall
be made except by means of a prospectus meeting the requirements of
Section 10 of the U.S. Securities Act of 1933, as amended. In
connection with the proposed transaction, Rocket has filed a
registration statement on Form S-4 that includes a joint proxy
statement of Renovacor and Rocket and also constitutes a prospectus
of Rocket. INVESTORS AND SECURITY HOLDERS OF RENOVACOR AND ROCKET
ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER
DOCUMENTS THAT HAVE BEEN AND WILL BE FILED WITH THE SEC CAREFULLY
AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY
CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description |
|
|
99.1 |
|
Presentation of Renovacor, Inc., dated
October 14, 2022. |
|
|
104 |
|
Cover Page Interactive Data File (embedded within
the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
RENOVACOR, INC. |
|
|
|
|
Date: October 14, 2022 |
|
|
|
By: |
|
/s/ Magdalene Cook, M.D.
|
|
|
|
|
|
|
President, Chief Executive Officer and
Director |

Exhibit
99.1 RENOVACOR CORPORATE PRESENTATION NYSE: RCOR October
2022

Forward
Looking Statements This presentation contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this communication
that do not relate to matters of historical fact should be
considered forward-looking statements, including statements
regarding the anticipated closing of and synergies related to the
transaction, expectations concerning market position, future
operations and other financial and operating information. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the following:
uncertainties as to the timing of the consummation of the proposed
transaction with Rocket Pharmaceuticals, Inc. (“Rocket”) and the
ability of the parties to consummate the proposed transaction; the
satisfaction of the conditions precedent to consummation of the
proposed transaction, including the approval of Renovacor’s and
Rocket’s stockholders; any litigation related to the proposed
transaction; disruption of Renovacor’s or Rocket’s current plans
and operations as a result of the proposed transaction; the ability
of Renovacor or Rocket to retain and hire key personnel;
competitive responses to the proposed transaction; unexpected
costs, charges or expenses resulting from the proposed transaction;
the ability of Rocket to successfully integrate Renovacor’s
operations and technology; diversion of managements’ attention from
ongoing business operations and opportunities; the ability of
Rocket to implement its plans, forecasts and other expectations
with respect to Renovacor’s business after the completion of the
transaction and realize additional opportunities for growth and
innovation; the ability of Rocket to realize the anticipated
synergies from the proposed transaction in the anticipated amounts
or within the anticipated timeframes or costs expectations or at
all; the ability to maintain relationships with Rocket’s and
Renovacor’s respective employees, customers, other business
partners and governmental authorities; competition; the impact of
the COVID-19 pandemic on Renovacor’s and Rocket’s businesses,
supply chain and labor force; risks related to the potential impact
of general economic, political and market factors on the companies
or the proposed transaction, including as a result of inflationary
pressures; the interest from patients and families for
participation in each of Rocket’s ongoing trials, expectations
regarding the delays and impact of COVID-19 on clinical sites,
patient enrollment, trial timelines and data readouts, expectations
regarding drug supply for ongoing and anticipated trials, actions
of regulatory agencies, which may affect the initiation, timing and
progress of pre-clinical studies and clinical trials of the parties
respective product candidates; the risk that the results of
preclinical studies and clinical trials may not be predictive of
future results in connection with future studies or trials; and the
risks and uncertainties described in the “Risk Factors” section of
Renovacor’s and Rocket’s respective annual and quarterly and
reports filed the Securities Exchange Commission. These risks, as
well as other risks related to the proposed transaction, will be
included in the registration statement on Form S-4 and proxy
statement/prospectus that will be filed with the Securities and
Exchange Commission (“SEC”) in connection with the proposed
transaction. While the list of factors presented here is, and the
list of factors to be presented in the registration statement on
Form S-4 are, considered representative, no such list should be
considered to be a complete statement of all potential risks and
uncertainties. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and neither Renovacor nor Rocket
assumes any obligation and does not intend to update or revise
these forward-looking statements, whether as a result of new
information, future events, or otherwise. Neither Renovacor nor
Rocket gives any assurance that it will achieve its expectations.
2

Rocket
Pharma to Acquire Renovacor Transaction Overview
•OnSeptember19,2022,RocketsignedadefinitiveagreementtoacquireRenovacorinanall-stock
transactionatanexchangeratioofapproximately0.1676(subjecttoadjustmentbasedonRenovacor'snet
cashatclosing),animpliedper-sharevalueof$2.60,basedonthevolumeweightedaveragetradingprice
ofRocket'scommonstockof$15.51forthe30tradingdaysthroughandincludingthesigningdate
•RCORshareholderstoownapproximately4.1%ofRocketimmediatelyfollowingtheclosing
•Impliedtotalequityvalueofapproximately$53MatclosebasedonRenovacor’scommonshares
outstandingandtheaccelerationandvestingofallearnoutshares
•TransactionpreservescashresourcesofthecombinedcompanyandallowsRenovacorshareholdersto
shareinfutureupside
•TransactionwasapprovedbytheBoardsofDirectorsofbothRocketandRenovacor,withvoting
agreementsinplacewithRenovacor'sandRocket'sdirectorsandofficersaswellascertainsignificant
shareholders Transaction expected to close by first quarter of 2023
3

Renovacor
Combination with Rocket Broadens Value Proposition for All
Stakeholders • Combines the resources, experience, and expertise of
both companies to create a category leader in cardiovascular gene
therapy Creates a Category Leader • Advances our mission to
transform the lives of heart failure patients through the power of
gene therapy • Synergies of the combined company expected to enable
efficient advancement of novel gene therapy candidates from
discovery through commercialization Accelerates Pipeline Expansion
• Leverages complementary capabilities and resources across
discovery, manufacturing, regulatory, and clinical development •
Leverages Rocket’s state-of-the-art ~100,000 square foot facility
dedicated to Research, State-of-the-Art Facilities Quality Control,
and AAV cGMP manufacturing, for the benefit of our non-clinical,
CMC, and clinical progress • Combined cash expected to extend
runway for the combined company into 2H 2024 and Extends Cash
Runway and through multiple potential value-enhancing clinical and
non-clinical milestones across a Adds Value Inflection Points
variety of pipeline programs 4

Mission
Renovacor’s mission is to deliver innovative precision therapies to
improve the lives of patients and families battling
genetically-driven cardiovascular and mechanistically- related
diseases Focus near-term on BAG3 Leverage the knowledge Translate
advances in dilated cardiomyopathy of the underlying genetic rare
disease populations (BAG3 DCM) AAV gene mechanisms of disease to to
more prevalent therapy, which targets the create transformative
populations where the underlying cause of this novel therapies
unmet medical need is devastating monogenic high form of heart
failure 5

Precision
Medicine is Changing the Treatment Paradigm for Patients and
Families with Cardiovascular Disease Seeks to address underlying
cause to deliver greater therapeutic benefit compared to current
standard-of-care. Addressing the personal & financial 1 burden
of multiple HF medications (avg. of ≥3/patient), implanted devices,
and heart transplant Advantages of precision 2 Expected to
eliminate the need for large patient studies . By focusing medicine
for on segments of the HF patient population most likely to benefit
heart failure (HF) Focus on endpoints that we believe are most
important to patients. Emphasizing improvements in quality of life
“Precision medicine strives to delineate disease using multiple
data sources…By defining disease at a deeper level, we can treat
patients based on an understanding of the molecular underpinnings
of their presentations, 3 rather than grouping patients into broad
categories with one-size-fits-all treatments.” - Dainis and Ashley
2018 1. Unlu et al, Circulation: Heart Failure. 2020 2. Teerlink et
al, NEJM 2021 3. Dainis AM, Ashley EA. JACC Basic Transl Sci. 2018
6

Diversified Pipeline
of Programs and Therapeutic Opportunities Program Potential
Indication Research / Discovery Preclinical Phase I Phase II Phase
III REN-001 BAG3-associated DCM (AAV9-BAG3) [RCSI] AAV9-BAG3 [IV]
BAG3-associated DCM Undisclosed CV AAV-BAG3 indication Undisclosed
CNS AAV-BAG3 indication DSG2-associated ACM AAV gene therapy
PKP2-associated ACM DSP-associated ACM Commercial rights held by
Renovacor. Development in connection with a research collaboration
with the University of Utah’s Nora Eccles Harrison Cardiovascular
Research and Training Institute. As a result of the combination
with Rocket, Renovacor has suspended current guidance regarding
preclinical and RCSI: retrograde coronary sinus infusion; IV:
intravenous; CV: Cardiovascular; CNS: Central nervous 7 clinical
timelines for its programs as it evaluates these system DCM:
Dilated Cardiomyopathy ACM: Arrhythmogenic Cardiomyopathy items
with Rocket BAG3- Mediated Genetic ACM Diseases

Lead
Program REN-001 for BAG3-associated Dilated Cardiomyopathy (BAG3
DCM)

1
Cardiovascular Disease is the #1 Cause of Death Worldwide
Cardiomyopathy • Primary disease of the heart muscle and a major
contributor to burden of cardiovascular disease 2 • Global
mortality 370,000 in 2020 was up 43% from 1990 Dilated
Cardiomyopathy (DCM) • Decrease in contractility causes heart’s
pumping chambers to enlarge • Most common form of cardiomyopathy
Familial DCM 2 • 20-50% of DCM patients; up to 40% have
identifiable genetic cause 3,4 • Scientific societies recently
endorsed clinical genetic testing for DCM patients and families
BAG3 DCM • Mutations in BCL2-associated athanogene 3 (BAG3) gene
are among the more common pathogenic genetic 5 variants observed in
DCM 6 • BAG3 expression is markedly diminished in patients with
severe ischemic or nonischemic DCM Currently approved therapies do
not address the underlying cause of disease 4. Musumuru K et al.
Circulation: Genomic and Precision Medicine 2020 1. Centers for
Disease Control and Prevention, Weekly Counts of Deaths by State
and Select Causes, 2019-2020 5. Kirk JA et al. J Clin Invest. 2021
2. American Heart Association Statistical Update: Heart Disease and
Stroke Statistics – 2022, mortality rate includes 6. Feldman AM et
al. J. Cell. Physiol. 2014 9 myocarditis 3. Ackerman MJ et al.
Heart Rhythm 2011

BAG3 DCM
is a Devastating Disease BAG3 DCM presents in otherwise healthy
individuals and rapidly progresses Caused by a genetic defect in
the BAG3 gene • Cardiovascular health is dependent on adequate
levels of functional BAG3 protein • BAG3 mutations typically lead
to reduced BAG3 protein levels 1 • Prevalence of BAG3 DCM in US
estimated to be as high as 30,000 patients and is expected to grow
with increasing genetic testing and disease awareness 2 • ~80%
penetrance at >40 years of age 2 At diagnosis, ~68% symptomatic,
~20% severely symptomatic with heart failure • Patients have
significant limitations on their activities of daily living, such
as employment, walking, attending to personal care, etc. 3 •
Severely symptomatic patients are frequently hospitalized for acute
decompensation High risk of progression to end stage disease • ~19%
of patients with BAG3 DCM require mechanical cardiac support, heart
transplant, or have HF-related 2,4,5 death at 12 months after
diagnosis, nearly twice the rate of similarly staged non-BAG3 DCM
patients Currently there are no approved therapies that address
underlying cause of disease 1. Virani et al., Circ. 2021; Steinberg
et al., Circ. 2012; Brouwers et al., Eur Heart J. 2013; Bhambhani
et al., Eur J Heart Fail. 2018; Kapoor et al., JACC:Heart Fail.
2016; Pfeffer et al., Lancet 2003; Balmforth et al., JACC:Heart
Fail. 2019; Felker et al., NEJM 2000; Haas et al., Eur Heart J.
2015; Kindel et al., J Card Fail. 2012; Pugh et al., Genet Med.
2014; Petretta et al., Am J Cardiol. 2011; McNally and Mestroni,
Circ Res. 2017; Sweet et al., Exp. Op. Orphan Drugs 2016; Ganesh et
al., Circ. 2013; Aragam et al., AHA Scient. Sess. 2021; Villard et
al., Eur. Heart J. 2011; Franaszczyk et al., J Trans Med. 2014;
Chami et al., Can J Cardiol. 2014; Arimura et al., Human Mut. 2011;
Dominguez et al., JACC 2018; Norton et al., Am J Human Gen. 2011.
2. Domínguez et al., JACC, 2018; 3. Ahmed A. Am J Cardiol. 2007;
4.McNamara et al., Circulation, 2001; 5. Kubanek M et al. JACC 2013
10

We Believe
Renovacor’s REN-001 is Well Positioned for Success Local
(retrograde coronary sinus infusion, We believe monogenic diseases
with well or RCSI) delivery allows lower total dose understood
biology are ideal targets for AAV GTxs • Reduces potential for
various vector toxicities • Targeting disease with known genetic
origin • May reduce burden on manufacturing • BAG3 mutations
well-documented as driver in DCM • Goal is to increase BAG3 levels
in DCM subjects Utilizes validated AAV9 capsid Non-immunogenic
one-time human BAG3 payload • AAV9 currently used in one approved
therapy • Therapeutic payload is human BAG3 gene (Zolgensma) and
widely in clinical trials • DCM patients are haploinsufficient and
produce low • AAV9 has demonstrated cardiac tropism levels of
native BAG3; therefore, the protein is not • Has high transduction
efficiency foreign and should not elicit an immune response •
Non-integrative vector REN-001 is designed to directly address the
underlying cause of BAG3 DCM by potentially increasing levels of
functional BAG3 protein in the heart GTx: gene therapy
11

BAG3
Regulates Multiple Important Functions in Cardiomyocytes Protein
quality control Cardiac contractility Enhances contractility by
linking Facilitates autophagy as a co- the β-adrenergic receptor
and L- chaperone with heat shock 2+ type Ca channel proteins,
recycling misfolded proteins Structural support Anti-apoptosis
Provides support for the Inhibits apoptosis (programmed sarcomere
by linking actin cell death) through binding of myofibrils with the
Z-disc BCL2 We believe that a gene therapy approach is best
positioned to restore the broad biological functions of BAG3 in the
heart Sources: Knezevic et al., 2016; Myers et al., 2018
12

Mutations
in BAG3 Reduce Levels of Protein and are Associated with Reduced
Force Generating Capacity in Heart Tissue from DCM Patients Lower
levels of BAG3 are associated with Most BAG3 mutations in DCM cause
reduced contractility in DCM patients reduced levels of BAG3
protein >80% of BAG3 DCM patients had mutations causing
Myofilament maximum force generating 1 capacity (F ) in DCM patient
tissue * haploinsufficiency, resulting in reduced levels of BAG3
protein max Healthy control DCM patient with BAG3 mutation BAG3
levels in DCM patients are positively correlated with force
generating 2 capacity 1st 2nd 3rd 4th BAG3 expression quartiles *
Patients with Lower idiopathic DCM Higher Red staining shows BAG3
protein in cardiac tissue REN-001’s goal is to increase expression
of BAG3 in the heart and potentially correct the underlying disease
in BAG3 DCM patients 1. Domínguez et al., JACC, 2018; 2. Martin et
al., Nature Communications, 2021 13

AAV9 BAG3
Prevents the Onset of Cardiac Impairment in a Genetic Mouse Model
of BAG3-associated DCM AAV9 BAG3 prevented the onset of reduced
BAG3 +/- mice have ~50% of BAG3 protein and ejection fraction
develop a reduced ejection fraction (EF) BAG3 protein levels
Ejection fraction Ejection fraction in WT and BAG3 +/- mice treated
at age 6-8 weeks with AAV9-GFP or AAV9-BAG3 WT mice: AAV-GFP or
AAV-BAG3 BAG3 +/- mice: AAV9 BAG3 treatment group BAG3 +/- mice:
Control group (AAV-GFP) ~50% BAG3 protein levels seen BAG3 +/- mice
develop reduced EF, in BAG3 +/- mice recapitulating the DCM
clinical phenotype *p=.04, .01 and .003 respectively at 2, 4 and 6
weeks for +/- AAV9-GFP vs. +/- AAV9-BAG3 arms; dose = 13 1×10
genome copies (gc). Weeks on X-axis denote time since treatment.
Sources: Haploinsufficiency data published in Myers VD., … Feldman
AM., J Cell Physiol. 2018; AAV-BAG3 administration adapted from
data published in Myers VD., … Feldman AM., JAMA Cardiol. 2018; and
unpublished data from the Feldman lab. 14

Renovacor’s Approach
to Cardiac Delivery Retrograde coronary sinus infusion (RCSI)
REN-001 is delivered into the coronary Overview of RCSI sinus using
a catheter § Coronary sinus (CS) - confluence of veins draining
heart into right atrium § Routine procedure for placement of left
ventricular pacemaker leads during cardiac resynchronization §
Emerging route of administration in cardiac gene therapy studies
Potential advantages of RCSI § Leverages currently used clinical
procedure and equipment § Ability to transduce heart using much
lower doses of AAV – Potential to maximize exposure of heart to AAV
– Reduced potential for various vector toxicities – Additional
potential benefits (e.g., manufacturing) 15

RCSI
Delivery of REN-001 Resulted in Successful Cardiac Transduction
Above 1 Key VCN Threshold at Doses <1e13 vg/kg in a Pilot Pig
Study VCN >1 seen in pig heart model Key Takeaways - Results
Published in JACC: BTS with REN-001 doses <1e13 vg/kg • Delivery
of REN-001 via RCSI results in robust transduction of a large
animal heart • Transcription of the BAG3 transgene detected • No
safety issues detected • Results informed design of ongoing GLP-
VCN of 1 toxicology and biodistribution study in healthy pig model
5e13 total vg; 1e14 total vg; 2.5e14 total vg; Vehicle Notes: Viral
genome per cardiomyocyte data are shown as the mean (+/- SEM) of 18
tissue sections 1.46e12 vg/kg 3.45e12 vg/kg 7.58e12 vg/kg taken per
heart (excluding values >3 standard deviations from the mean)
and assume 8 nuclei in each cardiomyocyte (Velayuthan et al., J Mol
Cell Cardiology, 2020); Vehicle n=1, 5e13 total vg REN-001 dose
groups (average of 1.46e12vg/kg) n=4, 1e14 total vg (average of
3.45e12vg/kg) n=2, 2.5e14 total vg VCN: vector copy number
(7.58e12vg/kg) n=1. 1. Myers et al., JACC:BTS, 2022 16

Results
Published in JACC BTS Demonstrate Diffuse Myocardial Transduction 1
in a Pilot Pig Study Regional Analysis of Transduction: Mean + SEM
Vector Genomes Per Cardiomyocyte for Rings 2, 3 and 4 5e13 total
vg; 1e14 total vg; 2.5e14 total vg; Vehicle 1.46e12 vg/kg 3.45e12
vg/kg 7.58e12 vg/kg Anterior 0.1+0.1 0.2+0.0 4.9+4.0 1.1+0.2
Anterolateral 0.0+0.0 0.2+0.1 0.6+0.4 0.8+0.3 Inferolateral 0.0+0.0
1.5+1.1 5.5+2.7 1.0+0.2 Inferior 0.0+0.0 1.6+1.2 0.6+0.1 2.9+1.8
Septum 0.0+0.0 0.6+0.5 1.0+0.2 1.1+0.2 Right ventricle 0.0+0.0
0.6+0.2 0.5+0.1 1.0+0.2 Notes: Mean ± SEM vector genomes per
cardiomyocyte, assuming 8 nuclei in each cardiomyocyte (Velayuthan
et al., J Mol Cell Cardiology, 2020) from five LV regions and the
RV free wall in rings 2-4 (excluding values >3 standard
deviations from the mean). # animals per group: Vehicle n=1, 5e13
total vg (average of 1.46e12 vg/kg) n=4, 1e14 total vg (average of
3.45e12 vg/kg) n=2, 2.5e14 total vg (7.58e12 vg/kg) n=1. 1. Myers
et al., JACC:BTS, 2022 17

Significant Progress
Made Across Key Ongoing Preclinical Studies Impaired survival
phenotype present in BAG3 DCM mouse model Natural history /
survival study of Preliminary / interim data indicating LV dilation
and functional decline, consistent with a DCM phenotype BAG3 mouse
New data and learnings were leveraged to optimize the design of the
dose-ranging study of REN-001 in model the same mouse model
Dose-ranging Dose-ranging study optimized to assess for multiple
efficacy measures at different timepoints, leveraging and
durability emerging data from the mouse natural history study
studies in BAG3 Durability of effect study remains underway mouse
model GLP toxicology Dosing completed in GLP toxicology study in
healthy Yucatan pigs using RCSI route of administration study LV:
Left ventricle; DCM: Dilated cardiomyopathy; RCSI: Retrograde
coronary sinus infusion 18

Renovacor’s Mission in
Action with Lead BAG3 DCM Program Segment patients into subtypes
based on the underlying Identify a condition with a high unmet
need. Global mortality cause of their disease to enable a precision
medicine approach 1 from cardiomyopathy was 370,000 in 2020 that
has the potential to improve upon the standard-of-care Designed
REN-001 to address the underlying cause of Focus on a disease
subtype with a well understood BAG3 DCM. Utilizes a validated AAV9
capsid to deliver a monogenic origin. BAG3 DCM: Caused by reduced
levels of functional copy of the BAG3 gene to cardiac cells BAG3
protein due to truncating mutations Demonstrate preclinical POC in
a model that we believe Potential successful cardiac transduction
with REN-001 accurately recapitulates human disease. Prevented
onset of delivered via RCSI at low vector dose. Local delivery may
reduce cardiac impairment with AAV9-BAG3 in genetic disease model
of potential vector-related toxicity as well as manufacturing
burden BAG3-DCM 1. American Heart Association Statistical Update:
Heart Disease and Stroke Statistics – 2022, mortality rate includes
myocarditis; POC: Proof-of-concept 19

REN-001
Clinical Development Plan

Proposed
Phase I/II Clinical Study Design for REN-001 Multi-center,
open-label, single-arm dose escalation study in BAG3 DCM patients
Evaluate Screen Cohort 1 Dose Level 1 n = 3-6 patients patients
Patients will be enrolled Screen Cohort 2 Evaluate sequentially
after DSMB Dose Level 2 patients patients n = 3-6 greenlight Key
inclusion criteria: Primary endpoint: Secondary endpoints: •
Subjects aged 18-75 with left ventricle (LV) dysfunction • Safety:
Frequency and severity of AEs and SAEs • 6-minute walk test •
Depressed LVEF as defined by AHA/ACC Guidelines • Efficacy: Cardiac
function by improvement in ejection • Exercise echocardiography
fraction • NYHA Class II-III HF symptoms • Kansas City
Cardiomyopathy Questionnaire • Elevated NT-proBNP • Serum biomarker
(NT-proBNP) • Genetic variant in BAG3 consistent with
haploinsufficiency LVEF: left ventricle ejection fraction; AE:
adverse event; SAE: serious adverse event; DSMB: data safety
monitoring board; NYHA; New York Heart Association 21

Advancing
our Precision Therapy Pipeline New Program in genetic
Arrhythmogenic Cardiomyopathy (ACM)

Precision
Gene Therapy in Development for Multiple Genetic Segments of
Arrhythmogenic Cardiomyopathy (ACM) ACM is a Devastating Heart
Muscle Disease Unmet Needs and Treatment Opportunities ACM is a
Disease of the Desmosome • Cardiomyopathy with a high • Current
approaches to prevent / treat arrhythmias arrhythmia burden, risk
of in ACM include antiarrhythmic drugs, catheter 2 sudden cardiac
death and, ablations, ICDs, and exercise restriction … potentially,
risk of heart failure • …but these fail to address the underlying
development; estimated genetics and disease biology, can be 1-2
prevalence of 1:1000-1:5000 burdensome and impact quality of life,
and patients Cell 1 2,5 can still experience breakthrough events •
Mutations in genes encoding desmosomal proteins seen in Cell 2 1
~50% patients and associated with cardiomyocyte uncoupling, cell
loss, and fibrofatty 3 Ventricular Arrhythmia in ACM Patient 1-3
Major unmet need for novel, precision remodeling therapy approaches
to prevent 4-5 • Mean age of diagnosis: ~30 arrhythmias in ACM
Sources: Desmosome image adapted from Pearson; 1. Austin K, Nat Rev
Cardiol. 2019; 2. Corrado D, New England Journal of Medicine
(2017); 3. Delmar M & McKenna W, Circ Res. (2010); 4. McNally E
(2017) in: Adam MP, Mirzaa GM, Pagon RA, GeneReviews®; 5. McKenna
W. Arrhythmogenic right ventricular cardiomyopathy: diagnostic 23
evaluation and diagnosis and treatment and prognosis. In: UpToDate,
Dardas D (Ed), UpToDate, Waltham, MA. (Accessed on June 24,
2022).

Precision
Gene Therapy in Development for Multiple Genetic Segments of
Arrhythmogenic Cardiomyopathy (ACM) 3 Mutations Causing ACM can
Disrupt Gap Junctions Positive Data from Initial Pilot Study •
Disease-causing mutations Disease-causing mutations can lower ü
Restoration of gap junction protein trafficking Cx43 expression at
the intercalated disc disrupt gap junction protein to the
intercalated disc in a genetic mouse expression at the intercalated
model of ACM disc; considered to be a key ü Significant reduction
in premature ventricular driver of increased arrhythmia 1-2
contractions (PVCs, hallmark proarrhythmic risk 4 events seen in
ACM ) in a genetic mouse model • Program designed to restore gap
junction protein trafficking and reduce the arrhythmia burden in
ACM Next steps: • Targeting the 3 largest genetic In vitro and in
vivo development across segments of ACM (PKP2, DSP, major genetic
segments of ACM 1-2 DSG2) (PKP2, DSP, and DSG2) Sources: Desmosome
image adapted from Pearson; 1. Corrado D, New England Journal of
Medicine (2017); 2. Austin K, Nat Rev Cardiol. 2019; 3. Palatinus
J. Circulation (2021); 4. 24 Gasperetti A. JAMA Cardiology
(2022).

Renovacor’s Mission in
Action with New Genetic ACM Program Identify a condition with a
high unmet need • ACM is a genetic disorder characterized by an
increased risk of potentially life-threatening arrhythmias,
myocardial dysfunction, and fibrofatty replacement of myocardial
tissue • Current treatments fail to address the underlying genetics
and disease biology Segment patients into subtypes based on the
underlying genetic drivers of their disease • Disease-causing
mutations, most commonly in genes encoding desmosomal proteins, can
be identified in approximately half of patients with ACM •
Plakophilin-2 (PKP2), desmoplakin (DSP), and desmoglein 2 (DSG2)
are the three largest genetic segments of ACM Seek to address a
causal disease pathway and leverage non- invasive clinical
measurements to facilitate efficient R&D • Focus on a precision
therapy approach to target underlying disease biology • Design
smaller and more cost-efficient patient studies • Focus on
endpoints that we believe are most important to patients Sources:
1. Austin K, Nat Rev Cardiol. 2019; 2. Corrado D, New England
Journal of Medicine (2017); 3. Delmar M & McKenna W, Circ Res.
(2010); 4. McNally E (2017) in: Adam MP, Mirzaa GM, Pagon RA,
GeneReviews®; 5. McKenna W. Arrhythmogenic right ventricular
cardiomyopathy: Diagnostic evaluation and diagnosis and treatment
and prognosis. In: UpToDate, Dardas D (Ed), UpToDate, Waltham, MA.
(Accessed on June 24, 2022.). 25

BAG3
Pipeline Expansion Opportunities

BAG3
Protein Levels are also Decreased in other Forms of Heart Failure
-/- 1 2 3 MLP and TAC mouse models Post-MI Pig Model HF Patients
Increasing BAG3 expression has the potential to impact additional
heart failure patient populations -/- HFrEF: Heart failure with
reduced ejection fraction; Notes: * p<0.05 between MI-GFP and
Sham-GFP, and between wild-type / sham and MLP / TAC mice 27 1.
Fang, X., et al., J Clin Invest., 2017; 2. Renovacor, data on file
(2021); 3. Feldman, AM et al., J. Cellular Physiology,
2014

1 AAV9
BAG3 Significantly Improved the EF in a Post-MI Mouse Model Post-MI
mice have reduced BAG3 expression AAV9 BAG3 significantly improved
the EF and AAV9 BAG3 increased protein levels in post-MI mice BAG3
protein levels A – Infarction; B – Week 1 echo; C – Treatment/
control injected retro- orbital at week 8 post-MI; D – Echo at
sacrifice, 23 days post- * treatment; p<0.0001; †p<0.0001 (1)
Mice develop a HF phenotype with reduced BAG3; (2) AAV9-BAG3
restored normal ejection fraction in post-MI mice; and (3)
AAV9-BAG3 had no impact on LVEF in control mice CLSQ:
Calsequestrin; Notes: MI: Mice randomized to receive myocardial
infarction * p<0.05 between MI-GFP and Sham-GFP; 1. Knezevic T.,
… Feldman, A.M., J Am Coll Cardiol Basic Trans Science. 2016; 1.
BAG3 has a known autoregulatory mechanism (Gentilella, A. &
Khalili, K., J Cell Biochem. 2009) 28

Corporate

Experienced Leadership
Team Marc Semigran, MD I CMO Magdalene Cook, MD I President and CEO
30+ years of experience treating HF and cardiomyopathy; Senior VP
of Medical 20+ years of experience in the life science industry
primarily in investing, Sciences and CMO at MyoKardia; experience
in developing and designing consulting and launching new ventures;
Principal, Aisling Capital and clinical trials for novel therapies
for cardiovascular and heart failure/HFpEF Board member of multiple
companies Matt Killeen, PhD, FACC, FHRS I CSO Elizabeth White, PhD
I CBO and Senior VP, Operations 15+ years of experience, spanning
cardiovascular disease research and biotech/pharma R&D and
strategy; Head of Cardiovascular Research at 30+ years of
biotech/pharma experience including in strategy, business BioMarin;
established cardiovascular therapeutic area and led the discovery
and development, new product planning, portfolio prioritization in
start-ups & large development of AAV-based gene therapies for
inherited heart diseases; companies expertise in genetic heart
disease biology and potential therapeutic opportunities Wendy
DiCicco I CFO Jiwen Zhang, PhD I Chief Regulatory Officer 25+ years
expertise in finance, strategy, M&A as well as executive roles
in public 20+ years of regulatory affairs and quality assurance
experience, with >10 years and private companies specifically in
cell and gene therapy Jordan Shin, MD, PhD, FACC I Senior VP,
Clinical Development and Kumar Dhanasekharan, PhD I Senior VP,
Technical Operations Translational Science 20+ years of CMC
development and manufacturing experience across complex 20+ of
expertise in clinical development, academic research and medical
practice protein therapeutics, monoclonal antibodies and in recent
years, AAV gene therapies. 30

Scientific
Advisory Board Experts in Cardiovascular Disease Arthur Feldman,
MD, PhD Douglas Mann, MD Renovacor, Founder and Chair of SAB Lewin
Prof. of Medicine, former Director of Cardiovascular Div.,
Washington Laura H. Carnell Professor of Medicine, Temple
University School of Medicine Former Chief of Cardiology UPMC Past
President, HFSA Past President HFSA, Assoc. of Professors of
Cardiology Lifetime Achievement Award, HFSA Editor-in-Chief, JACC
Basic Translational Science Lifetime Achievement Award, HFSA;
Distinguished Scientist Award ACC, 2019 Michael Bristow, MD, PhD
Professor of Medicine and former Head of Cardiology, Univ. of
Colorado Health Dennis McNamara, MD Sciences Professor of Medicine
and Dir. of the Heart Failure Research Center, UPMC Co-founder,
President and CEO, ARCA Biopharma Leading expert in the genetics of
dilated and hypertrophic cardiomyopathy Founder, Myogen National
Principal Investigator – IMAC I, II & III; GRAFH I & II
Lifetime Achievement Award, HFSA Credited with development of
science and clinical utility of b-blockers for HF Experts in Gene
Therapy R&D Joseph Glorioso III, PhD Richard Peluso, PhD
Professor in the Dept. of Microbiology and Molecular Genetics, UPMC
Founder and President, RWP BioConsulting, LLC Founding member and
past president of the American Society of Gene Therapy Retired Vice
President of Merck Vaccines & Biologics Bioprocess R&D
Co-founder and Chair of Scientific Advisory Board at Oncorus, Inc.
and Coda Previous faculty member of Microbiology Departments at
Thomas Jefferson Biotherapeutics University, University of
Minnesota, and Mt. Sinai School of Medicine Lee Sweeney, PhD
Professor in the Dept. of Pharmacology & Therapeutics,
University of Florida College of Medicine Much of Dr. Sweeney’s
research program is translational in focus and has produced highly
cited research on inherited forms of cardiovascular disease and on
the skeletal and cardiac aspects of muscular dystrophy.
31

Mission
and Value Proposition Renovacor’s mission is Lead BAG3 DCM program
targets the underlying cause of a to deliver innovative monogenic
disease with an AAV9-gene therapy precision therapies to improve
the lives of Proof-of-concept demonstrated in multiple preclinical
models patients and families battling genetically- Experienced
management and exceptional scientific advisors driven
cardiovascular and mechanistically- related diseases Backed by
strong institutional investor syndicate 32

RENOVACOR
For follow-up please contact: info@renovacor.com

Important
Additional Information Regarding the Transaction Will Be Filed With
the SEC In connection with the proposed transaction between
Renovacor and Rocket, Renovacor and Rocket have filed relevant
materials with the SEC, including a Rocket registration statement
on Form S-4 that includes a joint proxy statement of Renovacor and
Rocket and also constitutes a prospectus of Rocket, and a
definitive proxy statement will be mailed to stockholders of
Renovacor and Rocket, respectively. INVESTORS AND SECURITY HOLDERS
OF RENOVACOR AND ROCKET ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS THAT HAS BEEN INCLUDED IN THE REGISTRATION
STATEMENT ON FORM S-4 AND OTHER RELEVANT DOCUMENTS FILED OR TO BE
FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR
INCORPORATED BY REFERENCE IN THE JOINT PROXY STATEMENT/PROSPECTUS
(IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT
THE PROPOSED TRANSACTION, THE PARTIES TO THE PROPOSED TRANSACTION
AND THE RISKS ASSOCIATED WITH THE PROPOSED TRANSACTION. Investors
and security holders will be able to obtain, without charge, a copy
of the registration statement, the joint proxy statement/prospectus
and other relevant documents filed with the SEC (when available)
from the SEC’s website at http://www.sec.gov. Copies of the
documents filed with the SEC by Renovacor will be available free of
charge on Renovacor’s internet website at www.renovacor.com under
the tab “Investor & Media - Financials” or by contacting
Renovacor’s Investor Relations Department at
investors@renovacor.com. Copies of the documents filed with the SEC
by Rocket will be available free of charge on Rocket’s internet
website at www.rocketpharma.com under the tab “Investors – SEC
Filings”. Participants in the Solicitation Renovacor, Rocket and
certain of their directors, executive officers and other members of
management may be deemed to be participants in the solicitation of
proxies with respect to the proposed transaction. Information
regarding the persons who may, under the rules of the SEC, be
deemed participants in the solicitation of the shareholders of
Renovacor or Rocket in connection with the proposed transaction,
including a description of their direct or indirect interests, by
security holdings or otherwise, have been set forth in the joint
proxy statement/prospectus that has been filed with the SEC.
Information regarding Renovacor’s directors and executive officers
is contained in Renovacor’s definitive proxy statement, which was
filed with the SEC on April 14, 2022, and Renovacor’s Current
Reports on Form 8-K, filed with the SEC on March 28, 2022 and June
3, 2022 (as amended on June 24, 2022). Information regarding
Rocket’s directors and executive officers is contained in Rocket’s
definitive proxy statement, which was filed with the SEC on April
29, 2022. Security holders and investors may obtain additional
information regarding the interests of such persons, which may be
different than those of Renovacor’s or Rocket’s security holders
generally, by reading the joint proxy statement/prospectus and
other relevant documents regarding the transaction, which will be
filed with the SEC. You may obtain these documents (when they
become available) free of charge through the website maintained by
the SEC at http://www.sec.gov and from the Investor Relations
websites of Rocket or Renovacor as described above. No Offer or
Solicitation This presentation is not intended to and does not
constitute an offer to sell or the solicitation of an offer to
subscribe for or buy or an invitation to purchase or subscribe for
any securities or the solicitation of any vote or approval in any
jurisdiction pursuant to the proposed transaction or otherwise, nor
shall there be any sale, issuance or transfer of securities in any
jurisdiction in contravention of applicable law. This presentation
does not constitute a prospectus or prospectus equivalent document.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the U.S.
Securities Act of 1933, as amended. In connection with the proposed
transaction, Rocket has filed a registration statement on Form S-4
that includes a joint proxy statement of Renovacor and Rocket and
also constitutes a prospectus of Rocket. INVESTORS AND SECURITY
HOLDERS OF RENOVACOR AND ROCKET ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT HAVE BEEN AND WILL BE
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME
AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION. 34
Chardan Healthcare Acqui... (AMEX:CHAQ)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023
Chardan Healthcare Acqui... (AMEX:CHAQ)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023